Article Text

Download PDFPDF
CASE REPORT
Trisomy 5 as the sole chromosomal anomaly in acute lymphoblastic leukaemia
  1. Preeti Prerna M Vaswani,
  2. Teresita E Dumagay
  1. Section of Hematology, Department of Internal Medicine, Philippine General Hospital, University of the Philippines Manila, Manila, Philippines
  1. Correspondence to Dr Preeti Prerna M Vaswani, prernamvaswani{at}gmail.com

Summary

Trisomy 5 as the sole cytogenetic aberration in acute lymphoblastic leukaemia (ALL) is exceedingly rare. As such, its prognostic and therapeutic relevance remains unknown. We report a case of an 18-year-old young man who was diagnosed with B cell ALL with trisomy 5 as the sole chromosomal abnormality. He was treated with chemotherapy and went into complete remission. On the 14th month of treatment, he relapsed with central nervous system involvement characterised by leukaemic infiltration of the optic nerve and facial palsy. He subsequently underwent reinduction chemotherapy with aggressive intrathecal chemotherapy followed by posterior globe and whole brain radiation therapy. He is currently on his 26th month of treatment, in second remission, with complete resolution of leukaemic infiltrative optic neuropathy and facial paralysis. As more cases of this nature are reported, we will be able to determine the relevance of this distinct cytogenetic entity.

  • genetics
  • malignant and benign haematology

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Contributors PPMV contributed in the acquisition and analysis of patient data (history, images, consent) and drafting of the work. TED contributed in the final editing and approval of the paper for publishing.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.